GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (FRA:XE7C) » Definitions » Sale Of Business

Cardiff Oncology (FRA:XE7C) Sale Of Business : €0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Cardiff Oncology Sale Of Business?

Cardiff Oncology's sale of business for the three months ended in Dec. 2024 was €0.00 Mil. It means Cardiff Oncology gained €0.00 Mil from selling business. Cardiff Oncology's sale of business for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Compared with last quarter (€0.00 Mil in Sep. 2024 ), Cardiff Oncology gained the same money from selling business in Dec. 2024 (€0.00 Mil).


Cardiff Oncology Sale Of Business Historical Data

The historical data trend for Cardiff Oncology's Sale Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiff Oncology Sale Of Business Chart

Cardiff Oncology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Sale Of Business
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cardiff Oncology Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Sale Of Business Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cardiff Oncology Sale Of Business Calculation

The amount earned to sell business.


Sale Of Business for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardiff Oncology Sale Of Business Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's Sale Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardiff Oncology Business Description

Traded in Other Exchanges
Address
11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.

Cardiff Oncology Headlines

No Headlines